118 related articles for article (PubMed ID: 14577846)
21. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans.
Arbour NC; Lorenz E; Schutte BC; Zabner J; Kline JN; Jones M; Frees K; Watt JL; Schwartz DA
Nat Genet; 2000 Jun; 25(2):187-91. PubMed ID: 10835634
[TBL] [Abstract][Full Text] [Related]
22. The amino-terminal region of toll-like receptor 4 is essential for binding to MD-2 and receptor translocation to the cell surface.
Fujimoto T; Yamazaki S; Eto-Kimura A; Takeshige K; Muta T
J Biol Chem; 2004 Nov; 279(46):47431-7. PubMed ID: 15337750
[TBL] [Abstract][Full Text] [Related]
23. LPS, TLR4 and infectious disease diversity.
Miller SI; Ernst RK; Bader MW
Nat Rev Microbiol; 2005 Jan; 3(1):36-46. PubMed ID: 15608698
[TBL] [Abstract][Full Text] [Related]
24. MD-2 is required for the full responsiveness of mast cells to LPS but not to PGN.
Ushio H; Nakao A; Supajatura V; Miyake K; Okumura K; Ogawa H
Biochem Biophys Res Commun; 2004 Oct; 323(2):491-8. PubMed ID: 15369778
[TBL] [Abstract][Full Text] [Related]
25. Interaction of soluble form of recombinant extracellular TLR4 domain with MD-2 enables lipopolysaccharide binding and attenuates TLR4-mediated signaling.
Hyakushima N; Mitsuzawa H; Nishitani C; Sano H; Kuronuma K; Konishi M; Himi T; Miyake K; Kuroki Y
J Immunol; 2004 Dec; 173(11):6949-54. PubMed ID: 15557191
[TBL] [Abstract][Full Text] [Related]
26. Identification of LPS-binding peptide fragment of MD-2, a toll-receptor accessory protein.
Mancek M; Pristovsek P; Jerala R
Biochem Biophys Res Commun; 2002 Apr; 292(4):880-5. PubMed ID: 11944896
[TBL] [Abstract][Full Text] [Related]
27. A designed TLR4/MD-2 complex to capture LPS.
Brandl K; Glück T; Hartmann P; Salzberger B; Falk W
J Endotoxin Res; 2005; 11(4):197-206. PubMed ID: 16176655
[TBL] [Abstract][Full Text] [Related]
28. Human MD-2 confers on mouse Toll-like receptor 4 species-specific lipopolysaccharide recognition.
Akashi S; Nagai Y; Ogata H; Oikawa M; Fukase K; Kusumoto S; Kawasaki K; Nishijima M; Hayashi S; Kimoto M; Miyake K
Int Immunol; 2001 Dec; 13(12):1595-9. PubMed ID: 11717200
[TBL] [Abstract][Full Text] [Related]
29. Cutting edge: cell surface expression and lipopolysaccharide signaling via the toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages.
Akashi S; Shimazu R; Ogata H; Nagai Y; Takeda K; Kimoto M; Miyake K
J Immunol; 2000 Apr; 164(7):3471-5. PubMed ID: 10725698
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of TLR-4/MD-2 signaling by RP105/MD-1.
Divanovic S; Trompette A; Atabani SF; Madan R; Golenbock DT; Visintin A; Finberg RW; Tarakhovsky A; Vogel SN; Belkaid Y; Kurt-Jones EA; Karp CL
J Endotoxin Res; 2005; 11(6):363-8. PubMed ID: 16303092
[TBL] [Abstract][Full Text] [Related]
31. Lipopolysaccharide-binding protein down-regulates the expression of interleukin-6 by human gingival fibroblast.
Ren L; Leung WK; Loo TW; Jin L
J Periodontal Res; 2005 Oct; 40(5):407-16. PubMed ID: 16105094
[TBL] [Abstract][Full Text] [Related]
32. Membrane-anchored CD14 is required for LPS-induced TLR4 endocytosis in TLR4/MD-2/CD14 overexpressing CHO cells.
Shuto T; Kato K; Mori Y; Viriyakosol S; Oba M; Furuta T; Okiyoneda T; Arima H; Suico MA; Kai H
Biochem Biophys Res Commun; 2005 Dec; 338(3):1402-9. PubMed ID: 16263085
[TBL] [Abstract][Full Text] [Related]
33. The equine TLR4/MD-2 complex mediates recognition of lipopolysaccharide from Rhodobacter sphaeroides as an agonist.
Lohmann KL; Vandenplas ML; Barton MH; Bryant CE; Moore JN
J Endotoxin Res; 2007; 13(4):235-42. PubMed ID: 17956942
[TBL] [Abstract][Full Text] [Related]
34. MD-2 expression is not required for cell surface targeting of Toll-like receptor 4 (TLR4).
Visintin A; Halmen KA; Khan N; Monks BG; Golenbock DT; Lien E
J Leukoc Biol; 2006 Dec; 80(6):1584-92. PubMed ID: 16946018
[TBL] [Abstract][Full Text] [Related]
35. Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4.
Pålsson-McDermott EM; O'Neill LA
Immunology; 2004 Oct; 113(2):153-62. PubMed ID: 15379975
[TBL] [Abstract][Full Text] [Related]
36. Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to Toll-like receptor-4 aggregation and signal transduction.
Visintin A; Latz E; Monks BG; Espevik T; Golenbock DT
J Biol Chem; 2003 Nov; 278(48):48313-20. PubMed ID: 12960171
[TBL] [Abstract][Full Text] [Related]
37. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4.
Shimazu R; Akashi S; Ogata H; Nagai Y; Fukudome K; Miyake K; Kimoto M
J Exp Med; 1999 Jun; 189(11):1777-82. PubMed ID: 10359581
[TBL] [Abstract][Full Text] [Related]
38. [Relationships between LPS-tolerance and TLR4 as well as its signaling pathway].
Zhang DM; Mao BL
Sheng Li Ke Xue Jin Zhan; 2003 Jul; 34(3):277-9. PubMed ID: 14628483
[No Abstract] [Full Text] [Related]
39. Separate functional domains of human MD-2 mediate Toll-like receptor 4-binding and lipopolysaccharide responsiveness.
Re F; Strominger JL
J Immunol; 2003 Nov; 171(10):5272-6. PubMed ID: 14607928
[TBL] [Abstract][Full Text] [Related]
40. Identification of a novel isoform of MD-2 that downregulates lipopolysaccharide signaling.
Ohta S; Bahrun U; Tanaka M; Kimoto M
Biochem Biophys Res Commun; 2004 Oct; 323(3):1103-8. PubMed ID: 15381113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
